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Introduction: Patients with schizophrenia are at increased risk of suicide, but data from controlled studies of
pharmacotherapy in relation to suicide risk is limited.
Aim: To explore suicide risk in schizophrenia in relation to medication with antipsychotics, antidepressants,
and lithium.
Methods: Of all patients with a ﬁrst clinical discharge diagnosis of schizophrenia or schizoaffective disorder
in Stockholm County between 1984 and 2000 (n = 4000), patients who died by suicide within ﬁve years
from diagnosis were deﬁned as cases (n = 84; 54% male). Individually matched controls were identiﬁed
from the same population. Information on prescribed medication was retrieved from psychiatric records
in a blinded way. Adjusted odds ratios [OR] of the association between medication and suicide were
calculated by conditional logistic regression.
Results: Lower suicide risk was found in patients who had been prescribed a second generation antipsychotic
(clozapine, olanzapine, risperidone, or ziprasidone; 12 cases and 20 controls): OR 0.29 (95% conﬁdence interval
[CI], 0.09–0.97). When the 6 cases and 8 controls who had been prescribed clozapine were excluded, the
OR was 0.23 (95% CI 0.06–0.89). No signiﬁcant association was observed between suicide and prescription of
any antipsychotic, depot injection antipsychotics, antidepressants, SSRI, or lithium.
Conclusions: Lower suicide risk for patients who had been prescribed second generation antipsychotics may be
related to a pharmacological effect of these drugs, to differences in adherence, or to differences in other patient
characteristics associated with lower suicide risk.© 2013 Elsevier B.V. All rights reserved.1. Introduction
About 5 to 6% of patients with schizophrenia die from suicide
(Palmer et al., 2005; Nordentoft et al., 2011), and 4 to 8% of all suicides
are attributable to inpatient treated schizophrenia spectrum disorder
(Qin and Nordentoft, 2005; Reutfors et al., 2010b). Numerous studies
have investigated predictors of suicide in schizophrenia; some of the
established risk factors include previous suicide attempts, higher
premorbid function, depression, and poor adherence to treatment
(Hawton et al., 2005; Reutfors et al., 2010a).
Antipsychotic drugs are essential in reducing positive psychotic
symptoms and the need for hospitalization in schizophrenia (NICE,
2009). However, their effect on the risk for completed suicide still re-
mains a matter of debate (Ernst and Goldberg, 2004; Aguilar and Siris,miology (CPE), Department of
ty Hospital Solna, T2, SE-171 76
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ghts reserved.2007). Findings of reduced suicidal or self-injurious behavior in patients
using antipsychotics, mainly clozapine, have led to suggestions that an-
tipsychoticsmay also lower the risk of completed suicide (Meltzer et al.,
2003; Aguilar and Siris, 2007). Among the few controlled studies of an-
tipsychotic use and completed suicide in schizophrenia are two
register-based cohort studies from Finland. These have demonstrated
a reduction in suicide risk related to antipsychoticmedication in general
(Tiihonen et al., 2006), and a signiﬁcantly lower risk of suicide associat-
edwith clozapine use thanwith any other antipsychotic (Tiihonen et al.,
2009). However, a limitation in these studies was that some potential
confounding factors, including socioeconomic status, were not adjusted
for.
In addition to antipsychotics, other psychotropic drugs such as anti-
depressants and mood stabilizers are commonly used in schizophrenia
(Vares et al., 2011). However, although the beneﬁcial effect of lithium
on suicide risk in bipolar disorder is relatively well documented
(Cipriani et al., 2005), data on whether this extends to patients with
schizophrenia or schizoaffective disorder are lacking (Leucht et al.,
2007). There is also a paucity of studies about the effect on suicide risk
Table 1
Characteristics of cases (patients with a diagnosis of schizophrenia or schizoaffective
disorder who died by suicide, n = 84) and individually matched controls (patients with a
diagnosis of schizophrenia or schizoaffective disorder who did not die by suicide, n = 84).
Suicide cases Controls
n (%) n (%)
Diagnosis
Schizophreniaa 73 (87) 69 (82)
Schizoaffective disorderb 11 (13) 15 (18)
Age at diagnosis (years)
18–34 52 (62) 54 (64)
35–44 19 (23) 18 (21)
45–64 13 (15) 12 (14)
Sex
Men 45 (54) 50 (60)
Women 39 (46) 34 (40)
Age at onset of psychiatric symptoms
b18 years 5 (6) 10 (12)
18–24 years 37 (44) 38 (45)
25–29 years 19 (23) 26 (31)
≥30 years 23 (27) 10 (12)
Education
Primary school 23 (27) 29 (35)
Secondary school or higher 54 (64) 42 (50)
Unknown 7 (8) 13 (15)
a Diagnoses according to ICD-8: 295 (excluding 295.70); ICD-9: 295 (excluding 295H);
ICD-10: F20.
b Diagnoses according to ICD-8: 295.70; ICD-9: 295H; ICD-10: F25.
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2004). Recently, a register based cohort study found that current antide-
pressant use in schizophrenia compared with no use was associated
with a signiﬁcant reduction in risk of completed suicide (Tiihonen
et al., 2012).
When studying suicide risk in relation to drug use, clinical trials are
commonly impossible to perform for ethical reasons and because sui-
cides are rare, even in populations at increased suicide risk. Observa-
tional studies are therefore warranted to increase the knowledge of
pharmacotherapy in schizophrenia and its relation to suicide risk. We
performed a nested population based case–control study to assess
suicide risk in relation to prescription of antipsychotics, antidepressants,
and lithium in schizophrenia and schizoaffective disorder.
2. Methods
2.1. Study subjects
The source population for the study was identiﬁed in the Swedish
National Patient Register. This register contains individual-based informa-
tion on psychiatric hospitalizations with complete coverage of Stockholm
County since 1973. For each hospitalization, the register includes the
patient's unique civic registration number, dates of admission and dis-
charge, diagnoses at discharge, psychiatric department, and hospital. It
is compulsory for all in-patient facilities to submit data on discharge and
the register is therefore population-based. We identiﬁed the patients of
age 18 to 64 years who were discharged for the ﬁrst timewith a primary
(main) diagnosis of schizophrenia or schizoaffective disorder (index diag-
nosis; code 295 in the International Classiﬁcation of Disease 8th revision
(ICD-8), code 295 in ICD-9, and codes F20, F25 in ICD-10) frompsychiatric
departments in Stockholm County between June 1984 and December
2000 (N = 4000). All patients were then linked to the Swedish Cause
of Death Register, which is nation-wide and covers more than 99% of all
deaths in Sweden. We identiﬁed 84 individuals who had died by suicide
(codes E950–E959 in ICD-8 and ICD-9 and codes X60–X84 in ICD-10)
within ﬁve years from their index diagnosis. For each suicide case, one
control was individually matched from the source population. Matching
criteria were date (±1 year) and age (±5 years) at index diagnosis.
Each control had to be alive at the time of death of the corresponding sui-
cide case. After permission from the heads of the relevant psychiatric and
non-psychiatric medical departments, we traced the clinical records for
the 84 matched case–control pairs.
2.2. Data collection and deﬁnitions of exposures
The information about the prescribed pharmacological treatments
as well as of psychosocial and demographic factors was retrieved from
the clinical records of the cases and controls. To ensure that the time
for documented follow-up data was similar for each matched pair, a re-
search assistant truncated the control record at the date corresponding
to the date of death of the case. Data about the prescribed drugs were
collected until the day of death of the case and until the corresponding
day for the control. To make the data reviewer blind as to whether a re-
cord belonged to a case or to a control, the assistant also removed that
part of the clinical record that contained data regarding the death of
the case.
All antipsychotic drugs prescribed to the cases and controls were
included in the group ‘any antipsychotic’ and are listed in Table 2.
Four of these drugs were deﬁned as second generation antipsychotics
(SGAs), namely clozapine, olanzapine, risperidone, and ziprasidone.
The group ‘any antidepressant’ included SSRIs, SNRIs, tricyclic antide-
pressants, tetracyclic antidepressants, and MAO-inhibitors with the
drugs speciﬁed in Table 2. Lithiumwas studied separately. The following
formulations of lithiumhad been used: lithium, lithium citrate, and lith-
ium sulfate.2.3. Statistical analysis
Conditional logistic regressionwas used to estimate odds ratios (OR)
with 95% conﬁdence intervals (CI) for the associations between treat-
mentwith antipsychotic medications and death by suicide. The analysis
was conditioned on the risk-set structure deﬁned by the matching pro-
cess, with additional adjustment for sex, education, and age at onset of
symptoms. We also investigated the association between treatment
with SGAs, clozapine separately, depot injection antipsychotics, antide-
pressants, SSRIs separately and lithium on the one hand and death by
suicide on the other. The analyses were repeated after restricting the
timing of prescription (exposure) to onemonth and oneyear before sui-
cide in the cases and the corresponding dates in the matched controls.
We also investigated if there was any association between the number
of prescriptions for each drug category and the suicide risk (1 prescrip-
tion, 2 prescriptions,≥3 prescriptions). SAS statistical software (version
9.1) was used for all analyses.
2.4. Ethical permission
The study was approved by the ethics committee of Karolinska
Institutet, Stockholm, Sweden (No. 01-375).
3. Results
Table 1 summarizes the characteristics of the cases and controls. The
majority of patients received their diagnosis at an age younger than
35 years. The suicide risk estimates associated with these background
factors have been reported previously (Reutfors et al., 2009).
Table 2 displays the information on themedications prescribed prior
to the suicide for the suicide cases and controls. It also shows the relative
suicide risk estimates for exposed vs. unexposed patients expressed as
odds ratios (corresponding to suicide incidence rate ratios) (Pearce,
1993). Antipsychotic drugs had been prescribed to 99% of all the pa-
tients. The suicide risk was reduced by approximately 70% in patients
who had ever been prescribed a second generation antipsychotic
(clozapine, olanzapine, risperidone, or ziprasidone) compared to those
who had not (adjusted odds ratio [OR] = 0.29, 95% CI 0.09–0.97).
Table 2
Odds ratios (OR) with 95% conﬁdence intervals (CI) for the association between suicide and prescriptions of antipsychotics, antidepressants, and lithium.
Suicide cases Controls
n (%) n (%) OR (95% CI) Adjusted OR (95% CI)a
Any antipsychoticb
No 1 (1) 1 (1) N/A N/A
Yes 83 (99) 83 (99)
Clozapine, olanzapine, risperidone, or ziprasidone
No 72 (86) 64 (76) Reference Reference
Yes 12 (14) 20 (24) 0.33 (0.11–1.00) 0.29 (0.09–0.97)
Risperidone, olanzapine, or ziprasidone
No 76 (90) 68 (81) Reference Reference
Yes 8 (10) 16 (19) 0.27 (0.08–0.98) 0.23 (0.06–0.89)
Clozapine
No 78 (93) 76 (90) Reference Reference
Yes 6 (7) 8 (10) 0.67 (0.19–2.36) 0.75 (0.19–2.94)
Depot injection antipsychotic
No 47 (56) 52 (62) Reference Reference
Yes 37 (44) 32 (38) 1.26 (0.69–2.31) 1.28 (0.68–2.40)
Any antidepressantc
No 51 (61) 54 (64) Reference Reference
Yes 33 (39) 30 (36) 1.19 (0.61–2.31) 1.15 (0.58–2.28)
SSRI
No 77 (92) 74 (88) Reference Reference
Yes 7 (8) 10 (12) 0.67 (0.24–1.87) 0.68 (0.23–2.00)
Lithium
No 74 (88) 73 (87) Reference Reference
Yes 10 (12) 11 (13) 0.91 (0.39–2.14) 0.93 (0.38–2.24)
a Adjusted for sex, age at onset, and education.
b Alimemazine, dixyrazine, ﬂuphenazine, ﬂupentixol, haloperidol, clopenthixole, chlorpromazine, chlorprothixene, clozapine, levomepromazine, melperone, moperone, olanzapine,
perphenazine, pericyazine, pimozide, pipotiazine, prochlorperazine, raclopride, remoxipride, reserpine, risperidone, sulpiride, thioridazine, triﬂuoperazine, ziprasidone, and
zuclopenthixol.
c Amitriptyline, citalopram, ﬂuoxetine, ﬂuvoxamine, imipramine, clomipramine, lofepramin, maprotiline, mianserine, moclobemide, nortriptyline, paroxetine, sertraline, trimipramine,
and venlafaxine.
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the association substantially (OR = 0.23, 95% CI 0.06–0.89). Although the
point estimate was below unity for clozapine, the association was not
statistically signiﬁcant. There was no statistically signiﬁcant association
between depot-injection antipsychotics and suicide risk.
About one third of the cases and controls had a lifetime prescrip-
tion of an antidepressant. A history of having been prescribed any
type of antidepressant, SSRI or lithium did not affect the suicide
risk signiﬁcantly.
There was no statistically signiﬁcant association when the number
of recorded prescriptions of the drugs under study was examined.
Restricting the exposure time to onemonth or one year before the com-
pleted suicide, and the corresponding time for the controls, did not
show any statistically signiﬁcant association (data not shown). An iden-
tical number of cases and controls were recorded as using any of the
SGAs risperidone, ziprasidone or olanzapine in the last year (ﬁve cases
and ﬁve controls) and last month (one case and one control) before
the suicide. However, there was a slightly higher number of controls
than suicide cases with a recorded use of clozapine in the last year
(three cases and seven controls) and last month (one case and three
controls). This corresponds to a non-signiﬁcant lower suicide risk
among clozapine users in the respective time periods (adjusted OR
0.38, 95% CI 0.07–1.93 and OR of 0.34, 95% CI 0.04–3.6).4. Discussion
The main ﬁnding of this case–control study of suicide in schizophre-
nia was a lower suicide risk within ﬁve years from diagnosis among pa-
tients who had been prescribed a second generation antipsychotic.
Neither a medication history of antidepressants nor lithium did affect
the suicide risk. After adjusting the risk estimates for the potential con-
founders sex, education, and age at onset (Reutfors et al., 2009, 2010a),
the main ﬁnding became more pronounced.4.1. Strengths and limitations
A strength of this study is the use of a comprehensive national data-
base to identify a total schizophrenia patient cohort from which the
cases and controls were identiﬁed. This promotes the generalizability
of the ﬁndings. The prospective registration of all data in the case re-
cords means that no recall bias occurred, and a differential validity of
data between cases and controls is therefore unlikely. A potential bias
in the collection of data was minimized by blinded data retrieval. The
clinical diagnoses of schizophrenia reported to the patient register
have been shown to have a high concordance with the corresponding
diagnoses in the Diagnostic and Statistical Manual of Mental Disorders
(DSM-III-R or DSM-IV) (Ludvigsson et al., 2011).
A limitation of this study is that information about the patients' ad-
herence to prescribed drugs was not systematically recorded. In our
analyses we were also unable to assess the drug intake in the period
near in time to the suicide, as we believe the data were not reliable.
Many of the patients who committed suicide had not seen their psychi-
atrist in the time period near to the suicide and their current drug use
was therefore not recorded. The same situationwas found for the corre-
sponding time period in the controls. This means that we could not
know to what degree the patients were actually taking their prescribed
drug at the time of suicide. If we assume a similar degree of medication
non-adherence among subsequent suicide victims as among controls,
our risk estimates associated with drug classes would likely be de-
creased, and may therefore be conservative. If, on the other hand,
there was a differential non-adherence between cases and controls,
the true associations with drug classes could be either higher or lower
than those presented here. A further constraint was that the sample
size did not allow the evaluation of suicide risk for each individual anti-
psychotic and antidepressant drug or co-medicationwith other psycho-
tropic drugs. For the same reason, we were unable to assess the suicide
risk associated with the various drugs separately for schizophrenia
and schizoaffective disorder. Because of the complexity and frequent
419J. Reutfors et al. / Schizophrenia Research 150 (2013) 416–420changes in dosing regimens, we could not evaluate the relationship be-
tween drug dose and suicide risk.
When interpreting our results, one should also recognize the poten-
tial role of ‘confounding by indication’ inherent to observational studies
of drug use and the effects thereof. This means that patients who are
prescribed certain drugs can be assumed to be different than patients
who have not received such treatment. In other words, prescription of
SGAs may have been driven by unmeasured determinants of outcome
so that other characteristics than the drug itself have made the suicide
risk lower in users of SGAs.
4.2. Antipsychotics and suicide risk
Most of the previous studies suggesting a suicide lowering effect of
SGAs concern clozapine. Meltzer and Okayli (1995) noted a decrease
of suicidal behavior in an uncontrolled study of 88 treatment resistant
patients with schizophrenia who were started on clozapine. In a
subsequent randomized clinical trial, clozapine was compared with
olanzapine in 980 patients with schizophrenia or schizoaffective disor-
der classiﬁed as having a high risk of suicide because of current suicidal
thoughts or a previous suicide attempt (Meltzer et al., 2003). During an
18 month follow-up, therewas less suicidal behavior in patients treated
with clozapine compared with patients treated with olanzapine (HR
0.76, 95% CI 0.58–0.97), although ﬁve clozapine treated patients vs.
three olanzapine-treated patients committed suicide. Among the few
studies of completed suicide, a cohort study in Finland between 1996
and 2006 of 66,881 patients with schizophrenia, found that clozapine
use was associated with a reduced suicide risk (HR 0.34, 95% CI
0.20–0.57) when compared with perphenazine use (Tiihonen et al.,
2009). Comparable results of a signiﬁcantly lower suicide rate among
clozapine treated patients with schizophrenia (Reid et al., 1998) and
during current clozapine use compared with periods of non-use have
been reported (Walker et al., 1997). In contrast, however, Sernyak
et al. (2001) reported no signiﬁcantly lower suicide risk in 1415 patients
with schizophrenia who were clozapine users when compared with a
control group of 2830 patients with schizophrenia. Nevertheless, they
did identify a lower overall mortality among clozapine users, and a lim-
itation of the study was that they did not take into account when in the
history of illness the patient had received clozapine (Meltzer, 2002).
Studies of the risk of completed suicide in relation to use of other
SGAs than clozapine are few and comparisons of different SGAs have
not yet revealed any signiﬁcant differences in suicide risk, except for
clozapine (Tiihonen et al., 2009; Strom et al., 2011). As for results
from studies of suicidal behavior in general, an analysis of pooled data
from seven randomized clinical trials of antipsychotics found no differ-
ences in suicidal behaviorwhen comparing olanzapine, risperidone, and
quetiapine (Khan et al., 2001), and therewas no signiﬁcant difference in
the number of suicides in the treatment arms receiving an antipsychotic
compared to those who had received placebo (Khan et al., 2001;
Storosum et al., 2003). In the CATIE clinical trial there was no difference
in the rates of suicide attempts or suicidal ideation between users of the
ﬁrst generation antipsychotic perphenazine and SGAs (Lieberman et al.,
2005). One case–control study identiﬁed a lower risk of suicide at-
tempts among users of risperidone and olanzapine (Barak et al.,
2004); among 378 patients who attempted suicide, 16% were pre-
scribed SGAs compared to 37% of the control group. Likewise, another
study comparing 22 suicide attempters with 81 non-attempters found
a signiﬁcantly higher proportion of non-attempters to have used SGAs
than the suicide attempters (Altamura et al., 2003).
4.3. Antidepressants and lithium
We found no association between antidepressant use and suicide
risk. More than a third of both suicide cases and controls had been pre-
scribed antidepressants which can be compared with a French study of
3474 patients with schizophrenia, of whom about 20% were usingantidepressants (Montout et al., 2002). However, Roy (1982) reported
that 14 out of 30 schizophrenia suicide cases had a history of drug treat-
ment for depression compared to seven out of 30 controls, yielding a
suicide preventive association for antidepressants (p b 0.05). Similarly,
Tiihonen et al. (2012) found a signiﬁcantly lower suicide risk among pa-
tients with schizophrenia with current vs. no antidepressant use. One
reason for our contrasting result could be that we studied history of an-
tidepressant use and that depressed patients at higher risk of suicide
might have received antidepressants to a higher degree than patients
without depression. If the depression was thereby alleviated, some sui-
cides may have been prevented and such patients would then be found
among the controls and not among the cases in our study.
Lithiumwas used relatively frequently in our study sample, andmay
have been prescribedmainly for patients with prominentmood swings.
We did not ﬁnd any effect on suicide risk by lithium use, although the
absence of association should be interpreted with caution, as the same
mechanisms as suggested for antidepressants may have been in effect
also for lithium treatment.4.4. Potential mechanisms
A possible suicide risk lowering effect of clozapine and other SGAs
may have a number of pharmacological explanations. Although the
pharmacological differences between ﬁrst and second generation
antipsychotics may not be clear cut, some of the SGAs (e.g.
olanzapine, quetiapine, and clozapine) have appeared to show a bet-
ter antidepressant effect in schizophrenia than ﬁrst generation anti-
psychotics (Leucht et al., 2009). This may be important for suicide
prevention, because hopelessness and depression are prominent
risk factors for suicide in schizophrenia (Hawton et al., 2005;
Pompili et al., 2009). It has also been suggested that a higher seroto-
nergic effect in clozapine and certain other SGAs compared to ﬁrst
generation antipsychotics may reduce impulsivity, aggression, and
suicidality (Ernst and Goldberg, 2004).
Another reason may be that SGAs may have fewer side effects than
ﬁrst generation antipsychotics according to a number of reports (Leucht
et al., 2009). For example, clozapine has a low propensity to cause
akathisia or tardive dyskinesia, which are side effects that according
to case reports may increase suicidal behavior (Hawton et al., 2005;
Aguilar and Siris, 2007). Psychomotor agitation, restlessness and in-
somnia are other factors which may entail increased suicide risk in
schizophrenia (Hawton et al., 2005; Pompili et al., 2009). These fac-
tors may in certain situations be better treated by SGAs than by
ﬁrst generation antipsychotics to lower the risk for extrapyramidal
symptoms (Mantovani et al., 2013) and to improve the quality of
sleep (Miller, 2004). It is also possible that adherence to medication
was higher among those prescribed clozapine and other SGAs. The
frequent monitoring of clozapine patients may in itself be beneﬁcial
for lowering the suicide risk (Meltzer and Okayli, 1995;Walker et al.,
1997). Nevertheless, as clozapine use carries a risk of other serious
side effects limiting its use (Sernyak et al., 2001), a suicide risk low-
ering potential for other SGAs would be a great advantage. Because
the suicide risk elevation in schizophrenia and other psychoses is
most pronounced in the early phase of illness (Pompili et al., 2011),
the choice of pharmacological treatment may exert its biggest
inﬂuence on suicide risk in this period.4.5. Conclusion
The results of our study indicate that in schizophrenia suicide risk is
lower in patients who have used SGAs than in patients who have not.
Since our study is observational, this ﬁndingmay be due to a pharmaco-
logical effect, but also to other unmeasured characteristics of patients
who are prescribed SGAs.
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